Novartis Considers Takeover Bid for Biotech Firm Avidity Biosciences

Swiss pharmaceutical giant Novartis is reportedly exploring a potential acquisition of U.S.-based biotech company Avidity Biosciences, according to the Financial Times. The discussions are said to be in early stages, with Novartis aiming to strengthen its portfolio of treatments for rare genetic disorders.

Shares of Avidity surged 23% to $47.10 following the news, giving the company a market valuation of approximately $4.6 billion. Avidity is focused on developing therapies for rare muscle diseases, including its lead candidate del-zota, targeting a rare form of Duchenne muscular dystrophy. The company is also developing two other treatments for serious muscle disorders.

Sources familiar with the talks noted that while Novartis has expressed interest recently, there is no guarantee a deal will materialize, as other suitors could enter or negotiations might fall through. Avidity is working with advisers to evaluate strategic options. Both companies declined to comment.

This potential acquisition fits into Novartis’ broader strategy in 2025 to expand its drug pipeline through targeted deals. Earlier this year, Novartis agreed to acquire Anthos Therapeutics for $3.1 billion to boost its cardiovascular treatments and struck a deal to acquire Regulus Therapeutics for up to $1.7 billion, targeting kidney disease therapies. Additionally, Novartis partnered with Matchpoint Therapeutics in a deal worth up to $1 billion to develop oral medicines for inflammatory conditions.